drugset / Trial / NCT00922701

L-Carnitine in Peritoneal Dialysis

NCT00922701

Phase 2 Completed 4 enrolled Iperboreal Pharma Srl
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The development of glucose-sparing strategies able to provide an efficacious ultrafiltration profile represents one of the modern goals of peritoneal dialysis therapy. The study hypothesis is to evaluate the possibility to formulate peritoneal dialysis solutions containing L-carnitine as an osmotic agent to partially replace glucose.

Timeline

Start
2004-06
Primary completion
2004-10
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified 0.25 % Other